SVRA

Savara, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website avarapharma.com
Employees(FY) 28
ISIN US8051111016

Performance

+9.85%

+15.33%

+3.44%

-19.52%

-1.95%

YTD

-39.31%

Profile

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. is headquartered in Austin, Texas.

Advanced Technical Analysis

Technical Analysis of SVRA 2025-04-17

The stock exhibits a strong bullish sentiment with a Moving Average Score of 75 and a Technical Score of 75, indicating robust upward momentum. Although the Oscillators Score at 58 suggests a neutral stance, the overall indicators point towards a favorable outlook for the stock.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of SVRA

Stock Rank

Recent News & Updates

2025-04-11 04:05
Savara Announces New Employment Inducement Grant(Businesswire)
2025-04-07 04:05
Savara Announces Encore Presentations From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at Two Upcoming Scientific Conferences(Businesswire)
2025-03-26 19:05
Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update(Businesswire)
2025-03-26 04:45
Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital(Businesswire)
2025-03-26 04:05
Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP)(Businesswire)
2025-03-16 20:05
Savara to Present New Data From the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025(Businesswire)
2025-03-05 19:05
Savara Announces U.S. Launch of the aPAP ClearPath Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis (aPAP)(Businesswire)
2025-03-03 03:15
Savara Announces Participation in the Leerink Global Healthcare Conference(Businesswire)
2025-02-14 16:05
Savara Announces New Employment Inducement Grant(Business Wire)
2025-02-14 03:05
Savara Announces New Employment Inducement Grant(Businesswire)
2025-02-08 07:57
Positive Signs As Multiple Insiders Buy Savara Stock(Simply Wall St.)
2025-01-30 08:39
Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research(Business Wire)
2025-01-29 19:39
Savara Announces Manuscript on Long-Term Outcomes With Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research(Businesswire)
2025-01-29 16:05
Savara Announces Participation in Upcoming Healthcare Investor Conferences(Business Wire)
2025-01-29 03:05
Savara Announces Participation in Upcoming Healthcare Investor Conferences(Businesswire)
2024-12-29 09:54
Savara Inc. (NASDAQ:SVRA) is largely controlled by institutional shareholders who own 53% of the company(Simply Wall St.)
2024-12-23 03:05
Savara Announces New Employment Inducement Grant(Businesswire)
2024-12-20 08:33
Wells Fargo Initiates Coverage on Savara With Overweight Rating, $8 Price Target(MT Newswires)
2024-12-18 17:07
Savara Starts Biologics License Application Submission for Lung Disease Treatment Candidate(MT Newswires)
2024-12-18 16:05
Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)(Business Wire)
2024-12-18 03:05
Savara Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)(Businesswire)
2024-12-17 16:05
Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference(Business Wire)
2024-12-17 03:05
Savara Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference(Businesswire)
2024-11-25 09:18
Estimating The Fair Value Of Savara Inc. (NASDAQ:SVRA)(Simply Wall St.)
2024-11-22 16:05
Savara Announces New Employment Inducement Grant(Business Wire)
2024-11-22 08:05
Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024(Business Wire)
2024-11-22 03:05
Savara Announces New Employment Inducement Grant(Businesswire)
2024-11-21 19:05
Savara Announces Encore Presentation of Results from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the British Thoracic Society Winter Meeting 2024(Businesswire)
2024-11-21 06:20
Daily – Vickers Top Buyers & Sellers for 11/21/2024(Argus Research)
2024-11-19 06:38
Daily – Vickers Top Buyers & Sellers for 11/19/2024(Argus Research)

Page 1 of 5

previousnext

Disclaimer: The information provided here and on kavout.com is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout makes no recommendations regarding investment decisions based on this information. You are solely responsible for your investments. Please conduct your own research and consult qualified financial advisors before investing. Past performance does not guarantee future results.